Craig William Heise1, Tyler Gallo2, Steven C Curry1, Raymond L Woosley2. 1. Divisions of Medical Toxicology & Precision Medicine and Clinical Data Analytics and Decision Support, Department of Medicine, University of Arizona, College of Medicine - Phoenix. 2. Division of Clinical Data Analytics and Decision Support, Department of Medicine, University of Arizona, College of Medicine - Phoenix, Phoenix, Arizona, USA.
Abstract
OBJECTIVES: Pharmacogenomic testing (PGX) implementation is rapidly expanding, including pre-emptive testing funded by health systems. PGX continues to develop an evidence base that it saves money and improves clinical outcomes. Identifying the potential impact of pre-emptive testing in specific populations may aid in the development of a business case. METHODS: We utilized a software tool that can evaluate patient drug lists and identified groups of patients most likely to benefit from implementation of a PGX testing program in a major medical system population. RESULTS: Medication lists were obtained for sixteen patient groups with a total of 82 613 patients. The percent of patients in each group with testing 'Recommended', 'Strongly recommended', or 'Required' ranged from 12.7% in the outpatient pediatric psychiatry group to 75.7% in the any adult inpatient age >50 years group. Some of the highest yield drugs identified were citalopram, simvastatin, escitalopram, metoprolol, clopidogrel, tramadol, and ondansetron. CONCLUSION: We demonstrate a significant number of patients in each group may have benefit, but targeting certain ones for pre-emptive testing may result in the initial highest yield for a health system.
OBJECTIVES: Pharmacogenomic testing (PGX) implementation is rapidly expanding, including pre-emptive testing funded by health systems. PGX continues to develop an evidence base that it saves money and improves clinical outcomes. Identifying the potential impact of pre-emptive testing in specific populations may aid in the development of a business case. METHODS: We utilized a software tool that can evaluate patient drug lists and identified groups of patients most likely to benefit from implementation of a PGX testing program in a major medical system population. RESULTS: Medication lists were obtained for sixteen patient groups with a total of 82 613 patients. The percent of patients in each group with testing 'Recommended', 'Strongly recommended', or 'Required' ranged from 12.7% in the outpatient pediatric psychiatry group to 75.7% in the any adult inpatient age >50 years group. Some of the highest yield drugs identified were citalopram, simvastatin, escitalopram, metoprolol, clopidogrel, tramadol, and ondansetron. CONCLUSION: We demonstrate a significant number of patients in each group may have benefit, but targeting certain ones for pre-emptive testing may result in the initial highest yield for a health system.
Authors: Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle Journal: Annu Rev Genomics Hum Genet Date: 2022-05-10 Impact factor: 9.340
Authors: Timothy A Roberts; Jennifer A Wagner; Tracy Sandritter; Benjamin T Black; Andrea Gaedigk; Stephani L Stancil Journal: Clin Transl Sci Date: 2020-10-15 Impact factor: 4.689